OUR SCIENCE
PROPRIETARY PAN-AMYLOID TARGETING TO TRANSFORM TREATMENT & DIAGNOSIS
A NEW SCIENTIFIC PATH FORWARD
Our proprietary pan-amyloid targeting agents are capable of diagnosing and treating all types of systemic amyloidosis.
Attralus is focused on targeting the underlying pathology in all systemic amyloid diseases, with the goal of developing potential treatments for many subtypes of amyloidosis.
Pioneering PAR Therapeutics
Attralus is advancing the amyloidosis treatment paradigm by developing first-in-class therapies using our proprietary pan-amyloid removal (PAR) technology. With our differentiated approach, Attralus designs novel biologics to target all types of toxic amyloid with high specificity and superb binding properties to stimulate the immune system to remove amyloid. Our PAR therapeutics are unique in their ability to target, engage and remove all types of toxic amyloid.
A new treatment paradigm with amyloid removal

Precursor proteins cause amyloid fibril formation
![]() AMYLOID FIBRIL DEPOSITS Most patients have significant accumulation of amyloid at time of diagnosis |
HEART KIDNEY PERIPHERAL NERVES |
ATTRALUS SOLUTION
Amyloid
Removal
- Pan-amyloid removal
- All types of systemic amyloidosis
- All stages of disease
Our leading-edge capabilities for novel PAR therapeutics
|
PAR-PeptideOur proprietary amyloid binding peptide has a unique structure providing highly specific binding to multiple accessible sites on disease-causing amyloid deposits. Exquisite binding characteristics enable the peptide to target amyloid throughout the body to deliver the Fc to stimulate removal of deposits. PAR-SAPOur proprietary amyloid binding peptide has a unique structure providing highly specific binding to multiple accessible sites on disease-causing amyloid deposits. Exquisite binding characteristics enable the peptide to target amyloid throughout the body to deliver the Fc to stimulate removal of deposits. |
|
A bioactive IgG1 Fc-fusion region, a key component of PAR therapeutics, actively engages the innate immune system to signal macrophages to engulf and remove the amyloid through phagocytosis – following the therapeutic binding to the amyloid. |
|
Modular protein design allows the combination of our proprietary amyloid binding peptide with a variety of different biomolecules, offering the potential for multiple diagnostic and therapeutic strategies for the detection, targeting and removal of amyloid. |
Systemic amyloidosis patients imaged with AT-01
Examples of Images for Ph 1/2 trial of AT-01 in ATTR, AL and ALECT2 patients